Adicet Bio Inc
ACET0.691USD
+0.020+2.97%
交易中 （美东）报价延迟15分钟
57.11M总市值
亏损市盈率 TTM
关于 Adicet Bio Inc 公司
Adicet Bio, Inc. 是一家临床阶段的生物技术公司。该公司致力于推进现成的伽马德尔塔 T 细胞管线，这些细胞采用嵌合抗原受体 (CAR) 进行改造，以促进患者持久的活动。其主要候选产品 ADI-001 是一种表达靶向 CD20 的 CAR 的同类首创同种异体伽马德尔塔 T 细胞疗法，正在开发用于治疗自身免疫性疾病和复发或难治性侵袭性 B 细胞非霍奇金淋巴瘤 (NHL)。其管线还包括其主要临床前候选产品 ADI-270，这是一种针对肾细胞癌的装甲伽马德尔塔 CAR T 细胞候选产品，具有治疗其他 CD70+ 实体瘤和血液系统恶性肿瘤的潜力。其管线还有几个额外的内部伽马德尔塔 T 细胞疗法项目处于发现和临床前开发阶段，用于治疗血液系统恶性肿瘤和实体瘤。
公司简介
公司代码ACET
公司名称Adicet Bio Inc
上市日期Jan 26, 2018
CEOMr. Chen Schor, CPA
员工数量152
证券类型Ordinary Share
年结日Jan 26
公司地址131 Dartmouth Street
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02116
电话16174822333
网址https://www.adicetbio.com/
公司代码ACET
上市日期Jan 26, 2018
CEOMr. Chen Schor, CPA
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
158.73K
--
Dr. Lloyd Klickstein, M.D., Ph.D.
Dr. Lloyd Klickstein, M.D., Ph.D.
Independent Director
Independent Director
108.57K
+5.75%
Steve Dubin
Steve Dubin
Independent Director
Independent Director
22.70K
+35.12%
Dr. Andrew Sinclair, Ph.D.
Dr. Andrew Sinclair, Ph.D.
Independent Director
Independent Director
17.70K
+50.00%
Ms. Katie Peng
Ms. Katie Peng
Independent Director
Independent Director
17.70K
+50.00%
Mr. Michael J. Grissinger
Mr. Michael J. Grissinger
Independent Director
Independent Director
--
--
Mr. Blake Aftab, Ph.D.
Mr. Blake Aftab, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Nick Harvey
Mr. Nick Harvey
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Donald G. (Don) Healey, Ph.D.
Dr. Donald G. (Don) Healey, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Julie D Maltzman, M.D.
Dr. Julie D Maltzman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
158.73K
--
Dr. Lloyd Klickstein, M.D., Ph.D.
Dr. Lloyd Klickstein, M.D., Ph.D.
Independent Director
Independent Director
108.57K
+5.75%
Steve Dubin
Steve Dubin
Independent Director
Independent Director
22.70K
+35.12%
Dr. Andrew Sinclair, Ph.D.
Dr. Andrew Sinclair, Ph.D.
Independent Director
Independent Director
17.70K
+50.00%
Ms. Katie Peng
Ms. Katie Peng
Independent Director
Independent Director
17.70K
+50.00%
Mr. Michael J. Grissinger
Mr. Michael J. Grissinger
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
OrbiMed Advisors, LLC
13.84%
Tang Capital Management, LLC
9.94%
RA Capital Management, LP
9.12%
Goldman Sachs & Company, Inc.
4.54%
The Vanguard Group, Inc.
3.88%
Other
58.69%
持股股东
持股股东
占比
OrbiMed Advisors, LLC
13.84%
Tang Capital Management, LLC
9.94%
RA Capital Management, LP
9.12%
Goldman Sachs & Company, Inc.
4.54%
The Vanguard Group, Inc.
3.88%
Other
58.69%
股东类型
持股股东
占比
Hedge Fund
18.32%
Private Equity
13.84%
Venture Capital
13.12%
Investment Advisor/Hedge Fund
9.18%
Investment Advisor
7.68%
Research Firm
4.74%
Individual Investor
1.64%
Corporation
1.17%
Sovereign Wealth Fund
0.52%
Other
29.80%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
222
58.28M
70.47%
-19.00M
2025Q1
256
58.39M
70.64%
-25.11M
2024Q4
269
59.51M
72.24%
-24.49M
2024Q3
284
59.07M
71.72%
-29.65M
2024Q2
291
65.92M
80.26%
-25.36M
2024Q1
287
77.22M
95.63%
+2.21M
2023Q4
282
35.02M
80.66%
-21.60M
2023Q3
285
37.26M
86.17%
-19.04M
2023Q2
286
40.01M
93.07%
-16.43M
2023Q1
267
43.03M
100.17%
-13.36M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
OrbiMed Advisors, LLC
11.45M
13.84%
--
--
Mar 31, 2025
Tang Capital Management, LLC
8.22M
9.94%
+77.62K
+0.95%
Mar 31, 2025
RA Capital Management, LP
7.54M
9.12%
--
--
Mar 31, 2025
Goldman Sachs & Company, Inc.
3.75M
4.54%
-684.00
-0.02%
Mar 31, 2025
The Vanguard Group, Inc.
3.21M
3.88%
--
--
Mar 31, 2025
Abingworth Management Limited
2.95M
3.57%
--
--
Mar 31, 2025
Aquilo Capital Management, LLC
2.46M
2.97%
-75.00K
-2.96%
Mar 31, 2025
Acadian Asset Management LLC
2.04M
2.47%
+36.28K
+1.81%
Mar 31, 2025
Citadel Advisors LLC
1.25M
1.51%
+1.23M
+6067.69%
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
1.24M
1.49%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Fidelity Enhanced Small Cap ETF
0.01%
Avantis US Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Global X Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Biotechnology ETF
0%
查看更多
Fidelity Enhanced Small Cap ETF
占比0.01%
Avantis US Equity ETF
占比0%
Proshares Ultra Russell 2000
占比0%
iShares Micro-Cap ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
ProShares Hedge Replication ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
Global X Russell 2000 ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
iShares Biotechnology ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Sep 15, 2020
Merger
7<1
Sep 15, 2020
Merger
7<1
Sep 15, 2020
Merger
7<1
Sep 15, 2020
Merger
7<1
公告日期
类型
比率
Sep 15, 2020
Merger
7<1
Sep 15, 2020
Merger
7<1
Sep 15, 2020
Merger
7<1
Sep 15, 2020
Merger
7<1
